Day 02 | 2:30 PM - 3:30 PM
The Gut Microbiota and Immune Checkpoint Therapy of Cancer
The human gut microbiota represents an ecological niche established through billions of years of evolution. The approximately 350 different species in each human colon are relatively stable in each individual regulated by both positive and negative feedback loops between the microbes and the host. Factors that influence the gut bacterial abundance include diet, antibiotics, genetics, drugs. In preclinical and clinical studies, particular immunomodulatory strains can enhance or impair anti-cancer efficacy. We will discuss some of the advances made in the field in the last several years and the potential for prebiotic/probiotic combination treatments with other anti-cancer agents including immune checkpoint blockers to impact future cancer therapies.
Get To Know Dr. Arthur Frankel
Dr. Arthur Frankel is the Chief Medical Oncologist at USA Mitchell Cancer Institute in Mobile, Alabama. He specializes in Hematology and Medical Oncology and received his medical degree from Harvard Medical School with his residency and medical oncology fellowship at Stanford University.
Frankel is passionate about helping oncologists and the community navigate the rapid advances in cancer care. He says there is an “explosion of knowledge” that comes with new treatments and his “goal is to advance the quality of cancer care in Mobile and along the Gulf Coast." They are making new discoveries daily and able to impact lives across the entire Golf Coast.
Frankel believes that you do not need to be in a large city or cancer center to make a big impact! Having received over a dozen grants, and participated in just as many clinical trials, he currently has a pending grant for 5-year study on the "Role of Gut Microbiota in Modulating Immune Checkpoint Inhibitor Therapy for Cancer." Frankel has stated that immunotherapy is the most important advance in the past decade against cancer. He understands and is passionate about the connection between the immune system and the constantly evolving nature of cancer and tumors. By staying on top of the most recent translational research and treatment, he feels they can level the playing field and make it an "even battle."
Dr. Frankel's special interest is in melanoma and he has been co-inventor on 12 issued patents as well as author or co-author on more than 200 publications in peer-reviewed journals! He will undoubtedly be at the forefront of the next level of academic and research success at MCI and in the field of Oncology.